AKI Alerts for Acute Kidney Injury
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether sending alerts to doctors can prevent acute kidney injury (AKI) from worsening, reduce the need for dialysis, and lower the risk of death. Participants will be divided into two groups: one where electronic health record alerts for AKI are sent to doctors if a patient is expected to benefit, and another where alerts are not sent even if a benefit is expected. The trial seeks adults in the hospital who have recently shown signs of worsening kidney function, such as a significant increase in a specific blood test over a short period. Hospitalized individuals with AKI should consider these criteria to determine eligibility. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could improve patient care.
Do I have to stop taking my current medications for the AKI Alerts trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What prior data suggests that this alert is safe for patients with acute kidney injury?
Research has shown that electronic alerts for acute kidney injury (AKI) can impact patient outcomes. Some studies have found that these alerts help reduce severe AKI cases and improve recovery rates, suggesting they generally support better kidney health.
However, results are mixed. In some hospitals, alerts were linked to worse outcomes, possibly due to how hospitals used them. The safety of the alert system depends on hospital implementation and response. While no reports indicate direct harm from the alerts themselves, their effectiveness can vary.
In summary, while alerts show promise in some settings, their impact can differ based on hospital practices. No direct safety concerns for patients have been noted, but effectiveness can vary.12345Why are researchers excited about this trial?
Researchers are excited about the AKI Alerts trial because it explores a novel approach in managing Acute Kidney Injury (AKI) through predictive alerts rather than traditional medication or dialysis. Unlike standard treatments that focus on responding to kidney injury after it occurs, this trial examines whether real-time alerts, based on a probability score, can proactively identify patients likely to benefit from early intervention. This innovative use of technology aims to prevent kidney damage before it progresses, potentially transforming how AKI is managed and improving patient outcomes by focusing on prevention rather than just treatment.
What evidence suggests that this trial's AKI alert treatments could be effective?
Research has shown that electronic alerts for acute kidney injury (AKI) have not consistently reduced the worsening of AKI, the need for dialysis, or the risk of death. One study found that 21.3% of patients who received alerts experienced the main negative outcome, similar to 20.9% of those who did not receive alerts. A review of multiple studies found no clear improvement in patient survival or kidney health due to these alerts. While alerts have led to some changes in medical practices, they have not been proven to improve kidney function or other important patient outcomes. Therefore, current evidence leaves the effectiveness of AKI alerts uncertain. This trial will compare two approaches: one arm will generate alerts for patients with a probability of benefit greater than 0.5, while the other arm will generate alerts for those with a probability of benefit less than 0.5.12467
Who Is on the Research Team?
Francis Wilson, MD
Principal Investigator
Yale University
Are You a Good Fit for This Trial?
This trial is for adults over 18 who are hospitalized and have acute kidney injury (AKI) as shown by a significant rise in creatinine levels. It's not open to those already on dialysis, with very high initial creatinine, previous participation, hospice care, recent kidney transplant or opted out of health record research.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Randomization and Intervention
Participants are randomized into 'recommended' or 'anti-recommended' groups based on uplift scores, and alerts are generated accordingly
Follow-up
Participants are monitored for AKI progression, dialysis, or mortality
Extended Follow-up
Participants are monitored for secondary outcomes such as AKI best practices and readmission rates
What Are the Treatments Tested in This Trial?
Interventions
- Alert
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator